- Syngoi Technologies is a Basque biotechnology company established in 2021 by Columbus, specialising in synthetic DNA for advanced therapies
- This was the first investment made by the BV Healthcare Growth Innvierte I fund, which entered the company in 2024 as part of a capital increase alongside Columbus and Asahi Kasei Medical
- Artis BioSolutions will integrate the company into its ecosystem in order to establish an operational presence in the United States
Madrid, 21st January 2026. Buenavista Equity Partners, a private equity group specialising in the Spanish low/mid-market segment, announced today, alongside Columbus Venture Partners, an agreement to sell their stake in Syngoi Technologies, a company specialised in synthetic DNA for advanced therapies, to US-based firm Artis BioSolutions. The transaction is subject to final approval by the Spanish Council of Ministers.
Syngoi is a Contract Development and Manufacturing Organisation (CDMO) specialising in synthetic DNA for advanced therapies, a critical component for therapeutic applications such as mRNA vaccines, gene therapy, and gene editing. Based in Zamudio, Bizkaia, Syngoi operates state-of-the-art facilities and leverages a unique platform that streamlines production, reduces lead times, and achieves higher DNA purity compared to traditional methods.
In 2024, Syngoi Technologies completed a capital increase, which was subscribed by Buenavista through its BV Healthcare Growth Innvierte I fund, alongside Columbus Venture Partners, via its Columbus Life Science Fund II and Fund III, and Asahi Kasei Medical. This transaction enabled the company to significantly expand its manufacturing capacity and support more than 25 concurrent client projects.
Nuria Osés, Managing Partner in Buenavista’s Private Equity team, commented: “We are very pleased to have supported Columbus and the management team during this phase of Syngoi’s growth, a Spanish company with leading technology in advanced therapies. This is precisely the type of business we look to invest in at Buenavista: innovative companies with a validated technological foundation, already in the commercialisation phase or close to it, with the potential to drive growth and scalability. This transaction allows us to realise highly attractive returns for our investors, while also advancing a cutting-edge company whose technology will have a significant impact on the treatment of critical conditions and on improving people’s health.”
Driving Growth in an Expanding Sector
In 2024, Buenavista launched its new healthcare fund, BV Healthcare Growth Innvierte I, with commitments totalling €100 million and a hard cap of €150 million. The fund is managed in collaboration with Columbus Venture Partners through a joint venture that brings together both firms’ expertise in venture capital, private equity, and the healthcare sector. In addition, this vehicle is supported by the Spanish Centre for the Development of Technology and Innovation (CDTI).
The fund aims to invest in 10 to 12 healthcare companies, primarily in Spain, with investment tickets of up to €15 million per company, addressing the market need for growth capital in the healthcare sector. Investments focus on pharmaceuticals
and biotechnology, diagnostic solutions, precision medicine and medical devices, AI & Big Data, digital therapies and diagnostics, scale-up industrial manufacturing projects, scientific services (CROs and CDMOs), and healthcare services.
